Modifications of the radiosensitivity of a renal cancer cell line as a consequence of stable TIMP-1 overexpression

International Journal of Radiation Biology

Volumn 83, Issue 1, 2007, Pages 13-25

  Smyth, A ^a   Reid, H M ^b   Baker, A H ^c   McGlynn, H ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

DNA damage; Ionizing radiation; MMP 2; MMP 9; RCC; TIMP 1

Indexed keywords

COMPLEMENTARY DNA; GELATIN; GELATINASE A; GELATINASE B; LIPOFECTAMINE; REAGENT; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL GROWTH; CELL SURVIVAL; CLONOGENIC ASSAY; COMET ASSAY; CYTOMEGALOVIRUS; DNA DAMAGE; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; IONIZING RADIATION; MOLECULAR CLONING; NONHUMAN; PHENOTYPE; PLASMID; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN INTERACTION; RADIATION DOSE; RADIOSENSITIVITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SERUM; STAINING; WESTERN BLOTTING; ZYMOGRAPHY;

CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, RADIATION; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; MATRIX METALLOPROTEINASE 9; PLASMIDS; RADIATION TOLERANCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TRANSFECTION;

CYTOMEGALOVIRUS;

EID: 33847059149     PISSN: 09553002     EISSN: 13623095     Source Type: Journal    
DOI: 10.1080/09553000600983136     Document Type: Article

References (38)

1. Araya J, Maruyama M, Sassa K, Fujita T, Hayashi R, Matsui S, Kashii T, Yamashita N, Sugiyama E, Kobayashi M. 2001. Ionizing radiation enhances matrix-metalloproteinase 2 production in human lung epithelial cells. American Journal of Physiology and Lung Cell Molecular Physiology 280:L30-L38.
2. Birkedal-Hansen H, Moore WGI, Bodden MK, Windsor LJ, Birkedal-Hansen B, DeCarlo A, Engler JA. 1993. Matrix metalloproteinases: A review. Critical Reviews in Oral Biology and Medicine 4:197-250.
3. Bloomston M, Shafii A, Zervos EE, Rosemurgy AS. 2002. TIMP-1 overexpression in pancreatic cancer attenuates tumor growth, decreases implantation and metastasis, and inhibits angiogenesis. Journal of Surgery Research 102:39-44.
4. Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T. 2003. Regulation of matrix metalloproteinases: An overview. Molecular Cell Biochemistry 253:269-285.
5. Cockett MI, Murphy G, Birch ML, O'Connell L, Crabbe T, Milican AT, Hart IR, Docherty ASP. 1998. Matrix metalloproteinases and metastatic cancer. Biochemical Society Symposium 63:295-313.
6. Cordes N, Blaese MA, Plasswilm L, Rodemann HP, van Beuningen D. 2003. Fibronectin and laminin increase resistance to ionising radiation and the cytotoxic drug Ukrain® in human tumour and normal cells in vitro. International Journal of Radiation Biology 79:709-720.
7. Cordes N, Hansmeier B, Beinke C, Meineke V, van Beuningen D. 2003. Irradiation differentially affects substratum-dependent survival, adhesion, and invasion of glioblastoma cell lines. British Journal of Cancer 89:2122-2132.
8. Daza P, Schubler H, McMillan TJ, Girod SC, Pfeiffer P. 1997. Radiosensitivity and double-strand break rejoining in tumorigenic and non-tumorigenic human epithelial cell lines. International Journal of Radiation Biology 72:91-100.
9. Das U. 2002. A radical approach to cancer. Medical Science Monitor 8:RA79-RA92.
10. Hahn-Dantona E, Ramos-DeSimone N, Sipley J, Nagase H, French DL, Quigley JP. 1999. Activation of proMMP-9 by a plasmin MMP-3 cascade in a tumour cell model. Annals of the New York Academy of Sciences 878:372-387.
11. Heinzer H, Huland E, Huland H. 2001. Systemic chemotherapy and chemoimmunotherapy for metastatic renal cell cancer. World Journal of Urology 19:111-119.
12. Kallakury BV, Karikehalli S, Haholu A, Sheehan CE, Azumi N, Ross JS. 2001. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clinical Cancer Research 7:3113-3119.
13. Knox SJ, Goris ML, Wessels BW. 1992. Overview of animal studies comparing radioimmunotherapy with dose equivalent external beam irradiation. Radiotherapy and Oncology 23:111-117.
14. Kugler A, Hammerlein B, Thelen P, Kallerhoff M, Radzun HJ, Ringert HR. 1998. Expression of metalloproteinase 2 and 9 and their inhibitors in renal cell carcinoma. Journal of Urology 160:1914-1918.
15. Leeman MF, Curran S, Murray GI. 2003. New insights into the roles of matrix metalloproteinases in colorectal cancer development and progression. Journal of Pathology 201:528-534.
16. Liotta LA, Steeg PS, Stetler-Stevenson WG. 1991. Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell 64:327-336.
17. Makarewicz R, Zarzycka M, Kulinska G, Windorbska W. 1998. The value of postoperative radiotherapy in advanced renal cell cancer. Neoplasma 45:380-383.
18. Maskos K, Bode W. 2003. Structural basis of matrix metalloproteinases and tissue inhibitors of metalloproteinases. Molecular Biotechnology 25:241-266.
19. McElligott AM, Baker AH, McGlynn H. 1997. Matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase regulation of the invasion potential of a metastatic renal cancer cell line. Biochemical Society Transanctions 25:147S.
20. McKelvey-Martin VJ, Green MHL, Schmezer P, Pool-Zobel BL, DeMeo MP, Collins A. 1993. The single cell gel electrophoresis assay (comet assay): A European review. Mutation Research 288:47-63.
21. Mejean A, Oudard S, Thiounn N. 2003. Prognostic factors of renal cell carcinoma. Journal of Urology 169:821-827.
22. Nakopoulou L, Tsirmpa I, Alexandrou P, Louvrou A, Ampela C, Markaki S, Davaris PS. 2003. MMP-2 protein in invasive breast cancer and the impact of MMP-2/TIMP-2 phenotype on overall survival. Breast Cancer Research and Treatment 77:145-155.
23. Nelson AR, Fingleton B, Rothenberg ML, Matrisian L. 2000. Matrix metalloproteinases: Biological activity and clinical implications. Journal of Clinical Oncology 18:1135-1147.
24. Nguyen M, Arkell J, Jackson CJ. 2001. Human endothelial gelatinases and angiogenesis. International Journal of Biochemistry and Cell Biology 33:960-970.
25. Nirmala S, Jasti SL, Sawaya R, Kyritsis AP, Konduri SD, Ali-Osman F, Rao JS, Mohanam S. 2000. Effects of radiation on the levels of MMP-2, MMP-9 and TIMP-1 during morphogenic glial-endothelial cell interactions. International Journal of Cancer 88:766-771.
26. Nunez MI, McMillan TJ, Valenzuela MT, Ruiz de Almodovar JM, Pedraza V. 1996. Relationship between DNA damage, rejoining and cell killing by radiation in mammalian cells. Radiotherapy and Oncology 39:155-165.
27. Olive PL, Banath JP, Durand RE. 1990. Heterogeneity in radiation-induced DNA damage and repair in tumor and normal cells measured using the "comet" assay. Radiation Research 122:86-94.
28. Parsons SL, Watson SA, Brown PD, Collins HM, Steele RJC. 1997. Matrix metalloproteinases. British Journal of Surgery 84:160-166.
29. Pawlik TM, Keyomarsi K. 2004. Role of cell cycle in mediating sensitivity to radiotherapy. International Journal of Radiation, Oncology, Biology, Physics 59:928-942.
30. Ramnath N, Creaven PJ. 2004. Matrix metalloproteinase inhibitors. Current Oncology Reports 6:96-102.
31. Reid HM, McElligott AM, McGlynn H. 2001. Phenotypic alterations in Caki-1 cells as a consequence of TIMP-1 overexpression. Cancer Letters 169:189-198.
32. Slaton JW, Inoue K, Perrotte P, El-Naggar AK, Swanson DA, Fidler IJ, Dinney CP. 2001. Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma. American Journal of Pathology 158:735-743.
33. Smyth A, McGlynn H. 2005. Modifications of the radiosensitivity of a renal cancer cell line as a consequence of polyunsaturated fatty acid supplementation. Nutrition Research 25:65-77.
34. Sun Y, Wicha M, Leopold WR. 1999. Regulation of metastasis-related gene expression by p53: A potential clinical implication. Molecular Carcinogenesis 24:25-28.
35. Susskind H, Hymowitz MH, Lau YJ, Atkins HL, Hurewitz AN, Valentine ES, Meek AG, Zucker S. 2003. Increased plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in lung and breast cancer are altered during chest radiotherapy. International Journal of Radiation Oncology, Biology, Physics 56:1161-1169.
36. Takahashi M, Oka N, Naroda T, Nishitani MA, Kanda K, Kanayama HO, Kagawa S. 2002. Prognostic significance of matrix metalloproteinases-2 activation ratio in renal cell carcinoma. International Journal of Urology 9:531-538.
37. Tsuruda T, Costello-Boerrigter LC, Burnett JC Jr. 2004. Matrix metalloproteinases: pathways of induction by bioactive molecules. Heart Fail Reviews 9:53-61.
38. Wang JL, Sun Y, Wu S. 2000. Gamma-irradiation induces matrix metalloproteinase II expression in a p53-dependent manner. Molecular Carcinogenesis 27:252-258.